Clinical Research Directory
Browse clinical research sites, groups, and studies.
24-h Energy Expenditure and Anti-obesity Medication
Sponsor: University of Pisa
Summary
This study investigates the long-term effects of anti-obesity medications (Semaglutide and Tirzepatide) on energy metabolism (24-hour energy expenditure and substrate oxidation) and body composition via Dual-energy X-ray absorptiometry (DXA)
Official title: Effects of Anti-obesity Medications on 24h Energy Metabolism and Body Composition in Patients With Obesity
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
30
Start Date
2025-07-01
Completion Date
2026-12-01
Last Updated
2025-06-27
Healthy Volunteers
No
Conditions
Interventions
anti obesity medication
Patients with obesity or overweight, with at least one weight-related comorbidity who are expected to start treatment with Semaglutide (Wegovy) or Terzepatide (Mounjaro) at enrolment will be eligible to enrol into the study. Patients will be treated and observed according to normal clinical practice. Participation in this study does not limit the physicians' clinical decision making as to the most appropriate treatment for the patient during the course of the study